Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.32 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5509030 | 0.94 | EGFR (0.38) | EGFRFGFR2 | |
| SCHEMBL5506217 | 0.91 | MAPK1 (0.35) | EGFRPDPK1MAPK1FGFR2 | |
| SCHEMBL5507852 | 0.87 | GUCY1B2 (0.37) | PDPK1 | |
| SCHEMBL13233381 | 0.87 | MEN1 (0.42) | EGFRMAPK1DYRK1A | |
| SCHEMBL13898543 | 0.87 | MEN1 (0.42) | EGFRMAPK1DYRK1A | |
| SCHEMBL5504200 | 0.81 | MAPK1 (0.36) | EGFRMAPK1 | |
| SCHEMBL14437205 | 0.80 | EGFR (0.39) | EGFRFGFR2DYRK1A | |
| SCHEMBL5510707 | 0.79 | KDM1A (0.37) | EGFRPDPK1 | |
| SCHEMBL14437258 | 0.78 | MAPK1 (0.36) | EGFRMAPK1FGFR2DYRK1A | |
| SCHEMBL5505196 | 0.78 | SLC2A1 (0.36) | PDPK1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253285-B2 | Thiazolinone 4-monosubstituted quinolines | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | claimed |
| EP-1797085-A1 | THIAZOLINONE 4-MONOSUBSTITUTED QUINOLINES | F. Hoffmann-Roche AG (CH) | 2007-06-20 | — | — | EP | claimed |
| US-20060063805-A1 | Thiazolinone 4-monosubstituted quinolines | CHEN LI | 2006-03-23 | — | — | US | claimed |
| WO-2006029861-A1 | THIAZOLINONE 4-MONOSUBSTITUTED QUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-23 | — | — | WO | claimed |
| US-7749486-B2 | Tumor models employing green fluorescent protein | HOFFMANN-LA ROCHE INC. (US) | 2010-07-06 | — | — | US | disclosed |
| EP-2037270-A2 | Tumor models employing green fluorescent protein | F. HOFFMANN-LA ROCHE AG (CH) | 2009-03-18 | — | — | EP | disclosed |
| US-20070231789-A1 | Tumor models employing green fluorescent protein | QING WEIGUO | 2007-10-04 | — | — | US | disclosed |
| EP-1840570-A1 | Tumor models employing green fluorescent protein | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-03 | — | — | EP | disclosed |
| US-7253285-B2 | Thiazolinone 4-monosubstituted quinolines | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1797085-A1 | THIAZOLINONE 4-MONOSUBSTITUTED QUINOLINES | F. Hoffmann-Roche AG (CH) | 2007-06-20 | — | — | EP | disclosed |
| US-20060063805-A1 | Thiazolinone 4-monosubstituted quinolines | CHEN LI | 2006-03-23 | — | — | US | disclosed |
| WO-2006029861-A1 | THIAZOLINONE 4-MONOSUBSTITUTED QUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063805-A1 | Thiazolinone 4-monosubstituted quinolines | CDK1, CDK14, CDK17 | EGFR 2116/4885PDPK1 550/4885MAPK1 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.